Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Attal, N.
Right arrow Articles by Bouhassira, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Attal, N.
Right arrow Articles by Bouhassira, D.
NEUROLOGY 2004;62:218-225
© 2004 American Academy of Neurology

Systemic lidocaine in pain due to peripheral nerve injury and predictors of response

N. Attal, MD PhD, J. Rouaud, MD, L. Brasseur, MD, M. Chauvin, MD and D. Bouhassira, MD PhD

From INSERM E-332, Centre d’Evaluation et de Traitement de la Douleur, Hôpital Ambroise Paré, AP-HP, and Université Versailles-Saint-Quentin, France.

Address correspondence and reprint requests to Dr. Didier Bouhassira, INSERM E-332, Centre d’Evaluation et de Traitement de la Douleur, Hôpital Ambroise Paré, 9, avenue Charles de Gaulle, 92 100 Boulogne-Billancourt, France; e-mail: didier.bouhassira{at}apr.ap-hop-paris.fr

Objective: To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing.

Method: The authors randomized 22 patients to receive lidocaine 5 mg/kg IV during 30 minutes or placebo in a double-blind crossover design and 16 patients subsequently received mexiletine on an open basis titrated from 400 to 1,000 mg per day (mean 737 mg/day).

Results: Lidocaine induced a significant decrease in ongoing pain for up to 6 hours with a peak effect 60 to 120 minutes postinjection. The drug also decreased mechanical dynamic allodynia and static (punctate) mechanical allodynia/hyperalgesia, but not thermal allodynia and hyperalgesia. The effects of lidocaine and mexiletine on spontaneous pain intensity were significantly higher in patients with concomitant mechanical allodynia in comparison with those without allodynia.

Conclusions: These data indicate modality-specific antihyperalgesic effects of IV lidocaine in patients with peripheral nerve injury. Patients with mechanical allodynia may be good candidates for treatment with local anesthetic-like drugs and possibly with other sodium-channel blockers.

Received April 30, 2003. Accepted in final form September 24, 2003.




This article has been cited by other articles:


Home page
 JAMAHome page
E. Eisenberg, E. D. McNicol, and D. B. Carr
Efficacy and Safety of Opioid Agonists in the Treatment of Neuropathic Pain of Nonmalignant Origin: Systematic Review and Meta-analysis of Randomized Controlled Trials
JAMA, June 22, 2005; 293(24): 3043 - 3052.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.